Who owns LXEO?
Institutional ownership of Lexeo Therapeutics Inc. from Form 13F, Q2 2026
142 institutional managers reported holding Lexeo Therapeutics Inc. (LXEO) in Form 13F filings for Q2 2026, with 89,540,530 shares worth $417M. The largest reported holder was Montanova Capital, LLC. Managers that filed both quarters added a net 10,690,612 shares (+14.3%). 27 opened new positions and 21 sold out.
- Funds holding
- 142
- Value held
- $417M
- New / sold out
- 27 / 21
- Net shares, same filers
- +14.3%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of LXEO
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Montanova Capital, LLC | $29.7M | 7.1% | 6,384,200 | Added |
| Affinity Asset Advisors, LLC | $27.0M | 6.5% | 5,807,611 | Added |
| BlackRock, Inc. | $26.7M | 6.4% | 5,739,455 | Added |
| Ra Capital Management, L.p. | $23.3M | 5.6% | 5,000,000 | Unchanged |
| Frazier Life Sciences Management, L.P. | $22.5M | 5.4% | 4,824,725 | Added |
| State Street Corp | $20.3M | 4.9% | 4,354,757 | Added |
| Vestal Point Capital, LP | $20.1M | 4.8% | 4,320,000 | Trimmed |
| Paradigm Biocapital Advisors LP | $19.4M | 4.7% | 4,175,382 | Trimmed |
| Jupiter Topco LLC | $18.4M | 4.4% | 3,954,691 | First report |
| Orbimed Advisors LLC | $18.4M | 4.4% | 3,947,850 | Added |
| Citadel Advisors LLC | $18.1M | 4.4% | 3,898,570 | Added |
| Vanguard Capital Management LLC | $14.6M | 3.5% | 3,125,893 | Added |
| Millennium Management LLC | $13.2M | 3.2% | 2,833,622 | Added |
| Nantahala Capital Management, LLC | $12.1M | 2.9% | 2,600,000 | Added |
| Woodline Partners LP | $11.6M | 2.8% | 2,500,532 | Trimmed |
| Balyasny Asset Management L.P. | $11.2M | 2.7% | 2,412,742 | Added |
| Goldman Sachs Group Inc | $10.0M | 2.4% | 2,149,612 | Added |
| 683 Capital Management, LLC | $8.7M | 2.1% | 1,875,000 | Added |
| Geode Capital Management, LLC | $8.1M | 2.0% | 1,747,959 | Added |
| ADAR1 Capital Management, LLC | $7.3M | 1.7% | 1,565,950 | Added |
| Avoro Capital Advisors LLC | $6.9M | 1.7% | 1,489,189 | Trimmed |
| Qube Research & Technologies Ltd | $6.4M | 1.5% | 1,376,222 | Added |
| Dimensional Fund Advisors LP | $6.0M | 1.4% | 1,287,185 | Added |
| Spruce Street Capital LP | $4.3M | 1.0% | 928,593 | Unchanged |
| Blackstone Inc. | $4.2M | 1.0% | 904,959 | Unchanged |
Share of 13F holdings is each fund's shares as a share of the 89,540,530 LXEO shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Montanova Capital, LLC Added+$23.9M
- Nantahala Capital Management, LLC Added+$6.5M
- Millennium Management LLC Added+$5.7M
- Qube Research & Technologies Ltd Added+$4.2M
- Balyasny Asset Management L.P. Added+$3.8M
- State Street Corp Added+$3.7M
- Affinity Asset Advisors, LLC Added+$3.5M
- 683 Capital Management, LLC Added+$3.1M
- BlackRock, Inc. Added+$2.9M
- Aberdeen Group plc Added+$2.0M
Biggest sellers in Q2 2026
- Point72 Asset Management, L.P. Sold out-$9.6M
- Paradigm Biocapital Advisors LP Trimmed-$9.4M
- Octagon Capital Advisors LP Sold out-$6.3M
- Avoro Capital Advisors LLC Trimmed-$1.8M
- Woodline Partners LP Trimmed-$1.2M
- Two Sigma Investments, LP Sold out-$1.0M
- Y-Intercept (Hong Kong) Ltd Sold out-$818K
- Vestal Point Capital, LP Trimmed-$722K
- ExodusPoint Capital Management, LP Trimmed-$392K
- AQR Capital Management LLC Trimmed-$386K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $80.4M and sold $34.3M; 58 added and 39 trimmed.
Schedule 13D and 13G filings on LXEO
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-10-13JPMORGAN CHASE & CO SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-08-14ORBIMED ADVISORS LLC SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-04-13SUVRETTA CAPITAL MANAGEMENT, LLC SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-01-30VANGUARD GROUP INC SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2026-01-21BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2025-11-20Paradigm Biocapital Advisors LP SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2025-10-27RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
- 2025-08-14BALYASNY ASSET MANAGEMENT L.P. SCHEDULE 13G filed by Lexeo Therapeutics Inc.Schedule 13G
Questions about LXEO ownership
- Who owns LXEO stock?
- 142 institutional investment managers reported LXEO positions in their Form 13F filings for Q2 2026, holding 89,540,530 shares worth $417M in total. Montanova Capital, LLC reported the largest position.
- Are funds buying or selling LXEO?
- In Q2 2026, 27 managers opened new LXEO positions, 58 added, 39 trimmed and 21 sold out. Managers that filed in both quarters added a net 10,690,612 shares.
- How current is this LXEO institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to LXEO by CUSIP. Options are left out. LXEO news and filings · LXEO insider trades · Top funds